期刊
INTERNATIONAL JOURNAL OF ONCOLOGY
卷 49, 期 1, 页码 393-401出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2016.3524
关键词
pancreatic ductal adenocarcinoma; alpha-enolase; T cells; prognosis; T cell receptor repertoire
类别
资金
- Italian Ministry of University and Research
- University of Florence
- Associazione Italiana Ricerca sul Cancro (AIRC) [11643, 12182]
- University of Torino-Progetti di Ateneo [Rethe-ORTO11RKTW]
- Seventh Framework Program of European Community (European Pancreatic Cancer-Tumor Microenvironment-Network, EPC-TM-Net) [256974]
- Fondazione Internazionale di Medicina Sperimentale
- FAS
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with an average survival of 4-6 months following diagnosis. Surgical resection is the only treatment with curative intent, but resectable PDAC patients are in the minority. Also, unlike other neoplasms, PDAC is resistant to conventional and targeted chemotherapy. Innovative treatments, such as immunotherapy, can be very important and the study of the immune response is fundamental. We previously demonstrated that PDAC patients show tumor-infiltrating T cells specific to a-enolase (ENO1), a glycolytic enzyme over expressed by pancreatic tumor cells, which plays an important role in promoting cell migration and cancer metastasis. In the present study, we evaluate the functional anticancer proprieties of ENO1-specific T cells isolated from the peripheral blood of PDAC patients. Furthermore, comparing the T cell receptor repertoire of ENO1-specific peripheral and infiltrating tumor T cells from the same patient suggests that ENO1-specific T cells, despite having a different functional profile, can recirculate from the tumor to the periphery. Finally, of clinical relevance, the presence of peripheral ENO1-specific T cells has a prognostic value and significantly correlates with a longer survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据